{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T18:44:33Z","timestamp":1788201873593,"version":"build-2803163510"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"9","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Cystic fibrosis (CF) is a genetic disease associated with lung disease characterized by chronic pulmonary infection, increasingly caused by multiple drug-resistant pathogens after repeated antibiotic exposure, limiting antibiotic treatment options. Bacteriophages can provide a pathogen-specific bactericidal treatment used with antibiotics to improve microbiologic and clinical outcomes in CF.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>\n                                 <jats:italic toggle=\"yes\">Achromobacter<\/jats:italic> species isolates from sputum of a chronically infected person with CF, were assessed for susceptibility to bacteriophages: 2 highly active, purified bacteriophages were administered intravenously every 8 hours, in conjunction with a 14-day piperacillin\/tazobactam course for CF exacerbation. Sputum and blood were collected for metagenome analysis during treatment, with sputum analysis at 1-month follow-up. Assessments of clinical status, pulmonary status and laboratory evaluation for safety were conducted.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Bacteriophage administration was well-tolerated, with no associated clinical or laboratory adverse events. Metagenome analysis documented an 86% decrease in the relative proportion of <jats:italic toggle=\"yes\">Achromobacter<\/jats:italic> DNA sequence reads in sputum and a 92% decrease in blood, compared with other bacterial DNA reads, comparing pretreatment and posttreatment samples. Bacteriophage DNA reads were detected in sputum after intravenous administration during treatment, and at 1-month follow-up. Reversal of antibiotic resistance to multiple antibiotics occurred in some isolates during treatment. Stabilization of lung function was documented at 1-month follow-up.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Bacteriophage\/antibiotic treatment decreased the host pulmonary bacterial burden for <jats:italic toggle=\"yes\">Achromobacter<\/jats:italic> assessed by metagenome analysis of sputum and blood, with ongoing bacteriophage replication documented in sputum at 1-month follow-up. Prospective controlled studies are needed to define the dose, route of administration and duration of bacteriophage therapy for both acute and chronic infection in CF.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/inf.0000000000004000","type":"journal-article","created":{"date-parts":[[2023,6,23]],"date-time":"2023-06-23T13:28:25Z","timestamp":1687526905000},"page":"754-759","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Bacteriophage Therapy of Multidrug-resistant Achromobacter in an 11-Year-old Boy With Cystic Fibrosis Assessed by Metagenome Analysis"],"prefix":"10.1097","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3835-5064","authenticated-orcid":false,"given":"John S.","family":"Bradley","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Division of Infectious Diseases, University of California San Diego, and Rady Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamza","family":"Hajama","sequence":"additional","affiliation":[{"name":"Department of Biology and Viral Information Institute, San Diego State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"Akong","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Respiratory Medicine, University of California San Diego, and Rady Children\u2019s Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary","family":"Jordan","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Hospital San Diego Clinical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dayna","family":"Stout","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Hospital San Diego Clinical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan S.","family":"Rowe","sequence":"additional","affiliation":[{"name":"Department of Biology and Viral Information Institute, San Diego State University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas J.","family":"Conrad","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of California San Diego, San Diego, CA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Hingtgen","sequence":"additional","affiliation":[{"name":"Rady Children\u2019s Hospital San Diego Clinical Research"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca M.","family":"Segall","sequence":"additional","affiliation":[{"name":"Department of Biology and Viral Information Institute, San Diego State University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"S32","DOI":"10.1093\/jpids\/piac061","article-title":"Drugs, drugs, drugs: current treatment paradigms in cystic fibrosis airway infections.","volume":"11","author":"Cogen","year":"2022","journal-title":"J Pediatric Infect Dis Soc"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1542\/pir.2019-0212","article-title":"Cystic fibrosis.","volume":"42","author":"Dickinson","year":"2021","journal-title":"Pediatr Rev"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1016\/S0140-6736(20)32542-3","article-title":"Cystic fibrosis.","volume":"397","author":"Shteinberg","year":"2021","journal-title":"Lancet"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"ofaa389","DOI":"10.1093\/ofid\/ofaa389","article-title":"Lessons learned from the first 10 consecutive cases of intravenous bacteriophage therapy to treat multidrug-resistant bacterial infections at a single center in the United States.","volume":"7","author":"Aslam","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"S4","DOI":"10.1002\/ppul.25190","article-title":"Bacteriophage therapy for infections in CF.","volume":"56","author":"Chan","year":"2021","journal-title":"Pediatr Pulmonol"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1146\/annurev-med-080219-122208","article-title":"Phage therapy for antibiotic-resistant bacterial infections.","volume":"73","author":"Hatfull","year":"2022","journal-title":"Annu Rev Med"},{"key":"R7-20250614","first-page":"70","article-title":"The potential of bacteriophage therapy in the treatment of paediatric respiratory infections.","volume":"44","author":"Jones","year":"2022","journal-title":"Paediatr Respir Rev"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.3390\/v13071268","article-title":"The safety and toxicity of phage therapy: a review of animal and clinical studies.","volume":"13","author":"Liu","year":"2021","journal-title":"Viruses"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.3390\/microorganisms10081671","article-title":"How metagenomics has transformed our understanding of bacteriophages in microbiome research.","volume":"10","author":"Inglis","year":"2022","journal-title":"Microorganisms"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00705-019-04511-7","article-title":"Characterization of sixteen Achromobacter xylosoxidans phages from abidjan, Cote d\u2019Ivoire, isolated on a single clinical strain.","volume":"165","author":"Essoh","year":"2020","journal-title":"Arch Virol"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"2191","DOI":"10.1007\/s00705-017-3347-8","article-title":"Characterization and genome comparisons of three achromobacter phages of the family Siphoviridae.","volume":"162","author":"Dreiseikelmann","year":"2017","journal-title":"Arch Virol"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"220121","DOI":"10.1183\/16000617.0121-2022","article-title":"Phage therapy for pulmonary infections: lessons from clinical experiences and key considerations.","volume":"31","author":"Mitropoulou","year":"2022","journal-title":"Eur Respir Rev"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1097\/MCP.0000000000000864","article-title":"Advancing bacteriophages as a treatment of antibiotic-resistant bacterial pulmonary infections.","volume":"28","author":"Satta","year":"2022","journal-title":"Curr Opin Pulm Med"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1016\/S1473-3099(21)00612-5","article-title":"Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review.","volume":"22","author":"Uyttebroek","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.mib.2019.03.005","article-title":"Stronger together? Perspectives on phage-antibiotic synergy in clinical applications of phage therapy.","volume":"51","author":"Segall","year":"2019","journal-title":"Curr Opin Microbiol"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.chom.2017.10.001","article-title":"Three-dimensional microbiome and metabolome cartography of a diseased human lung.","volume":"22","author":"Garg","year":"2017","journal-title":"Cell Host Microbe"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"e00375","DOI":"10.1128\/mSystems.00375-19","article-title":"Molecular and microbial microenvironments in chronically diseased lungs associated with cystic fibrosis.","volume":"4","author":"Melnik","year":"2019","journal-title":"mSystems"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"12050","DOI":"10.3390\/ijms222112050","article-title":"Multi-omics study of keystone species in a cystic fibrosis microbiome.","volume":"22","author":"Silveira","year":"2021","journal-title":"Int J Mol Sci"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1038\/s41522-016-0002-1","article-title":"Ecological networking of cystic fibrosis lung infections.","volume":"2","author":"Quinn","year":"2016","journal-title":"npj Biofilms Microbiomes"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1038\/s41591-019-0437-z","article-title":"Engineered bacteriophages for treatment of a patient with a disseminated drug-resistant Mycobacterium abscessus.","volume":"25","author":"Dedrick","year":"2019","journal-title":"Nat Med"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"2990","DOI":"10.1002\/ppul.24945","article-title":"Combining bacteriophages with cefiderocol and meropenem\/vaborbactam to treat a pan-drug resistant Achromobacter species infection in a pediatric cystic fibrosis patient.","volume":"55","author":"Gainey","year":"2020","journal-title":"Pediatr Pulmonol"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/v13010060","article-title":"A case of phage therapy against pandrug-resistant Achromobacter xylosoxidans in a 12-year-old lung-transplanted cystic fibrosis patient.","volume":"13","author":"Lebeaux","year":"2021","journal-title":"Viruses"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"fuab048","DOI":"10.1093\/femsre\/fuab048","article-title":"Mechanisms and clinical importance of bacteriophage resistance.","volume":"46","author":"Egido","year":"2022","journal-title":"FEMS Microbiol Rev"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"e00954","DOI":"10.1128\/AAC.00954-17","article-title":"Development and use of personalized bacteriophage-based therapeutic cocktails to treat a patient with a disseminated resistant Acinetobacter baumannii infection.","volume":"61","author":"Schooley","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"26717","DOI":"10.1038\/srep26717","article-title":"Phage selection restores antibiotic sensitivity in MDR Pseudomonas aeruginosa.","volume":"6","author":"Chan","year":"2016","journal-title":"Sci Rep"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.3390\/pharmaceutics14071425","article-title":"Bacteriophage and bacterial susceptibility, resistance, and tolerance to antibiotics.","volume":"14","author":"Chen","year":"2022","journal-title":"Pharmaceutics"},{"key":"R29-20250614","doi-asserted-by":"crossref","first-page":"e00756","DOI":"10.1128\/msystems.00756-19","article-title":"Quantitative models of phage-antibiotic combination therapy.","volume":"5","author":"Rodriguez-Gonzalez","year":"2020","journal-title":"mSystems"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"5725","DOI":"10.1038\/s41467-022-33294-w","article-title":"Bacteriophage-antibiotic combination therapy against extensively drug-resistant Pseudomonas aeruginosa infection to allow liver transplantation in a toddler.","volume":"13","author":"Van Nieuwenhuyse","year":"2022","journal-title":"Nat Commun"}],"container-title":["Pediatric Infectious Disease Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004000","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,15]],"date-time":"2025-06-15T00:08:06Z","timestamp":1749946086000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/INF.0000000000004000"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":28,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/inf.0000000000004000","relation":{},"ISSN":["0891-3668"],"issn-type":[{"value":"0891-3668","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,19]]}}}